Where more than one mutation was identified in an actionable gene, there was either a clear hierarchy of action—e.g., NSCLC specimen G150739T had both an exon 19 deletion and p.T790M mutation in EGFR, meaning the patient would not respond to first generation EGFR TKIs but rather may benefit from a third generation drug [46]—or the same action was appropriate for both mutations, e.g., melanoma specimen G151372L had BRAF p.V600M and p.V600G mutations, both of which are likely to benefit from a BRAF inhibitor [25,47]. Here, EGFR is linked to melanoma.